27237-21-4

Basic information

• Product Name: 3-(4-NITROPHENOXY)BENZOIC ACID
• Synonyms: AKOS BC-0782;3-(4-NITROPHENOXY)BENZOIC ACID
• CAS NO: 27237-21-4
• Molecular Formula: C₁₃H₉NO₅
• Molecular Weight: 259.21
• Mol File: 27237-21-4.mol
• Article Data: 10

Chemical Properties

• Melting Point: 183 °C
• Boiling Point: 438.0±25.0 °C(Predicted)
• Appearance: /
• Density: 1.405±0.06 g/cm3(Predicted)
• PKA: 3.91±0.10(Predicted)
• CAS DataBase Reference: 3-(4-NITROPHENOXY)BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-NITROPHENOXY)BENZOIC ACID(27237-21-4)
• EPA Substance Registry System: 3-(4-NITROPHENOXY)BENZOIC ACID(27237-21-4)

Safety Data

• Hazardous Substances Data: 27237-21-4(Hazardous Substances Data)

Upstream product

• 284462-55-1 ethyl 3-(4'-nitrophenoxy)benzoate 
• 100-00-5 4-chlorobenzonitrile 
• 108-39-4 3-methyl-phenol 
• 7781-98-8 ethyl-3-hydroxybenzoate 
• 99-06-9 3-Carboxyphenol 
• 350-46-9 4-Fluoronitrobenzene 
• 2303-25-5 3-methyl-4'-nitrodiphenyl ether 

Downstream Products

• 54579-63-4 4-(3-carboxyphenoxy)aniline 
• 71708-64-0 N-methyl-3-(4-nitrophenoxy)benzamide 
• 1383627-70-0 3-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N,N-dimethylbenzamide 
• 41370-84-7 3-(4-nitrophenoxy)benzoyl chloride 
• 1253119-92-4 2,5-bis(hexyloxy)-N'1,N'4-bis(3-(4-nitrophenoxy)benzoyl)terephthalohydrazide 
• 1253119-91-3 2-(5-(4-t-butylphenyl)-1,3,4-oxadiazole-2-yl)-5-(5-(3-(4-(2-(2-hydroxyphenyl)-4,5-diphenyl-1H-imidazole-1-yl)phenoxy)phenyl)-1,3,4-oxadiazole-2-yl)benzene-1,4-diol 
• 1253119-87-7 N'-1-(4-t-butylbenzoyl)-2,5-bis(hexyloxy)-N'-4-(3-(4-nitrophenoxy)benzoyl)terephthalohydrazide 
• 1253119-95-7 2,5-bis(5-(3-(4-aminophenoxy)phenyl)-1,3,4-oxadiazole-2-yl)benzene-1,4-diol 
• 1253119-94-6 2,5-bis(5-(3-(4-nitrophenoxy)phenyl)-1,3,4-oxadiazole-2-yl)benzene-1,4-diol 
• 1253119-93-5 5,5'-(2,5-bis(hexyloxy)-1,4-phenylene)bis(2-(3-(4-nitrophenoxy)phenyl)-1,3,4-oxadiazole) 
• 1253119-90-2 2-(5-(3-(4-aminophenoxy)phenyl)-1,3,4-oxadiazole-2-yl)-5-(5-(4-t-butylphenyl)-1,3,4-oxadiazole-2-yl)benzene-1,4-diol 
• 1253119-89-9 2-(5-(4-t-butylphenyl)-1,3,4-oxadiazole-2-yl)-5-(5-(3-(4-nitrophenoxy)phenyl)-1,3,4-oxadiazole-2-yl)benzene-1,4-diol 
• 1253119-88-8 2-(2,5-bis(hexyloxy)-4-(5-(3-(4-nitrophenoxy)phenyl)-1,3,4-oxadiazole-2-yl)phenyl)-5-(4-t-butylphenyl)-1,3,4-oxadiazole 
• 284462-55-1 ethyl 3-(4'-nitrophenoxy)benzoate 

Relevant articles and documents

Synthesis and properties of 1,3,4-oxadiazole-containing bismaleimides with asymmetric structure and the copolymerized systems thereof with 4,4′-bismaleimidodiphenylmethane

Two novel bismaleimide monomers containing 1,3,4-oxadiazole and asymmetric structure, i.e., 2-[4-(4-maleimidophenoxy)phenyl]-5-(4-maleimidophenyl)-1,3,4- oxadiazole (p-Mioxd) and 2-[3-(4-maleimidophenoxy)phenyl]-5-(4-maleimidophenyl)- 1,3,4-oxadiazole (m-Mioxd), were designed and synthesized. The chemical structures of the monomers were confirmed using Fourier transform infrared spectroscopy (FTIR), 1H NMR and 13C NMR spectroscopy and elemental analysis. The thermal properties of the monomers were investigated by differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). The results indicate that the incorporation of the 1,3,4-oxadiazole and asymmetric structure could improve the solubility and processability of the BMI monomers and the thermal stability of the resins. Composites composed of glass cloth and 4,4′-bismaleimidodiphenylmethane (BMDM), which were modified with 2.5, 5 and 10 wt% p-Mioxd and m-Mioxd, respectively, were also prepared. The TGA and DMA results demonstrate that the resulting composites have excellent thermal stability with high residual weight percentage at 700 °C (>45%) and Tg (>450 °C).

Life beyond kinases: Structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors

Of great interest in recent years has been computationally predicting the novel polypharmacology of drug molecules. Here, we applied an "induced-fita€ protocol to improve the homology models of 5-HT2A receptor, and we assessed the quality of these models in retrospective virtual screening. Subsequently, we computationally screened the FDA approved drug molecules against the best induced-fit 5-HT2A models and chose six top scoring hits for experimental assays. Surprisingly, one well-known kinase inhibitor, sorafenib, has shown unexpected promiscuous 5-HTRs binding affinities, Ki = 1959, 56, and 417 nM against 5-HT 2A, 5-HT2B, and 5-HT2C, respectively. Our preliminary SAR exploration supports the predicted binding mode and further suggests sorafenib to be a novel lead compound for 5HTR ligand discovery. Although it has been well-known that sorafenib produces anticancer effects through targeting multiple kinases, carefully designed experimental studies are desirable to fully understand whether its "off-targeta€ 5-HTR binding activities contribute to its therapeutic efficacy or otherwise undesirable side effects.

omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.